Letter to the EditorReversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia
Section snippets
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
Contributions. E.M.O. S.G., A.S.P. contributed equally to this work. They conceived and wrote the article. B.R. was responsible for molecular analysis. All authors approved the final version of the manuscript.
References (10)
- et al.
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia
Leuk Res
(2009) - et al.
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
Blood
(2007) - et al.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
N Engl J Med
(2010) - et al.
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure
J Clin Oncol
(2007) - et al.
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Haematologica
(2010)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2011 Elsevier Ltd. All rights reserved.